Medherant is building a sustainable transdermal drug delivery company that generates value for patients, partners and investors by levering its unique TEPI Patch® technology.
Medherant is focused on developing innovative products to treat pain and CNS diseases which we intend to license for commericalisation. The Company is also formulating TEPI patch products for third parties who want to deliver their drugs through the skin.
Medherant has two potential sources of revenue - licensing products it has developed and licensing the TEPI technology for products it has formulated for others. We expect to receive licensing fees and royalties on sales of products incorporating the TEPI technology. The Company expects to secure its first deal in 2019.